文献速递肾小球疾病遗传性与小管间质肾病

膜增生性肾小球肾炎:已非同一疾病,治疗可能需要大不相同

Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

膜增生性肾小球肾炎(MPGN)可为原发性或继发于感染、自身免疫病和血液病。基于免疫荧光,MPGN分为补体介导的C3肾病(C3G)和免疫复合物介导的MPGN(IC-MPGN)。在原发性C3G和IC-MPGN患者队列中,无监督层级聚类识别出四种致病模式,具有特定组织学和临床特征及遗传和获得性补体异常。当前常用药物如皮质类固醇和免疫抑制剂常无效,抗C5单抗依库珠单抗仅偶用于个案或小系列,仅少数患者缓解。多种靶向补体系统不同层次的药物正在研究中,但临床试验因疾病异质性而具有挑战性,需表征每位患者以匹配特定补体异常与干预类型。

要点

  • MPGN分为补体介导的C3G和免疫复合物介导的IC-MPGN,但遗传和获得性补体异常提示二者为异质性谱系而非独立疾病。
  • 原发性C3G和IC-MPGN中识别出四种致病模式,为更准确诊断和靶向治疗提供基础。
  • 当前皮质类固醇和免疫抑制剂常无效,抗C5单抗仅少数患者缓解,需根据补体异常匹配干预。

核心结论

  • 原发性C3G和IC-MPGN是异质性谱系,基于补体异常模式而非传统分类,需个体化匹配靶向治疗。

研究设计与样本

  • 综述性文章,基于PubMed来源,讨论MPGN的分类、发病机制及治疗进展。
  • 在原发性C3G和IC-MPGN患者队列中采用无监督层级聚类分析。

主要发现

  • 在原发性C3G和IC-MPGN队列中,无监督层级聚类识别出四种 distinct 致病模式,具有特定组织学和临床特征及遗传和获得性补体异常。
  • C3G和IC-MPGN中均发现遗传和获得性补体异常,提示二者为异质性谱系而非独立疾病。
  • 依库珠单抗在个案或小系列中仅少数患者达到缓解,异质性反应可能与终末补体激活程度有关。

关键数值与推荐

  • 基于免疫荧光,MPGN分为补体介导的C3G和免疫复合物介导的IC-MPGN。
  • 原发性C3G和IC-MPGN中识别出四种致病模式。
  • 当前药物如皮质类固醇和免疫抑制剂常无效;依库珠单抗仅少数患者缓解。

临床怎么用

  • 需对每位患者进行表征,将特定补体异常与干预类型匹配。
  • 传统免疫抑制剂常无效,应关注补体靶向药物研究进展。

局限性

  • 临床试验因疾病异质性而具有挑战性。
  • 依库珠单抗证据仅来自个案或小系列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Membranoproliferative glomerulonephritis (MPGN) is a pattern of glomerular injury that may be primary or secondary to infections, autoimmune diseases and haematological disorders. Primary C3G and IC-MPGN are rare and the prognosis is unfavourable. Based on immunofluorescence findings, MPGN has been classified into complement-mediated C3 glomerulopathy (C3G) and immune complex-mediated MPGN (IC-MPGN). However, this classification leaves a number of issues unresolved. The finding of genetic and acquired complement abnormalities in both C3G and IC-MPGN indicates that they represent a heterogeneous spectrum rather than distinct diseases. An unsupervised hierarchical clustering in a cohort of patients with primary C3G and IC-MPGN identified four distinct pathogenetic patterns, characterized by specific histologic and clinical features, and genetic and acquired complement abnormalities. These results provide the groundwork for a more accurate diagnosis and the development of targeted therapies. The drugs that are currently used, such as corticosteroids and immunosuppressants, are frequently ineffective in primary C3G and IC-MPGN. Eculizumab, an anti-C5 monoclonal antibody, has been used occasionally in single cases or small series. However, only a few patients have achieved remission. This heterogeneous response could be related to the extent of terminal complement activation, which may vary substantially from patient to patient. Several drugs that target the complement system at different levels are under investigation for C3G and IC-MPGN. However, clinical trials to test new therapeutics will be challenging and heavily influenced by the heterogeneity of these diseases. This creates the need to characterize each patient to match the specific complement abnormality with the type of intervention.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Noris M, Daina E, Remuzzi G, et al. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrol Dial Transplant. 2023. PMID: 34596686. doi:10.1093/ndt/gfab281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。